In 2019, the US FDA approved bremelanotide subcutaneous injection (Vyleesi, AMAG Pharmaceuticals) for the treatment of acquired, generalised hypoactive sexual desire disorder (HSDD) in premenopausal women making it only the second approved pharmacotherapy for female sexual dysfunction and the first melanocortin-based medicine to reach clinical approval
Customized Exercise Regimens Boosts Medication Efficacy: Regular exercise not only aids in weight loss but also enhances the effectiveness of GLP-1 medications, leading to improved results
The large 2025 JACC meta-analysis of 99,599 patients found consistent MACE reduction regardless of whether patients had diabetes, obesity, CKD, or heart failure
No strenuous physical activity Avoid exercise or vigorous activity for 24 hours to prevent increased blood flow, which can cause Botox to spread or reduce its effectiveness
Okra & Chitosan Extracts Plant-based nutrients that contribute to balanced wellness